GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1.

GSK-872 is a potent and selective RIPK3 (receptor-interacting protein kinase-3) inhibitor.

GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183.

GSK9311 is a potent and highly selective inhibitor of the BRPF bromodomain (BRPDF1 pIC50 = 6.0; BRPDF2 pIC50 = 4.3).

GSK-A1 is a potent inhibitor of PI4KA. In vitro using HEK-AT1 cells, GSK-A1 had an IC50 of about 3 nM.

GSK-F1 is a potent inhibitor of PI4KA.

GSK-J1 is a potent and selective inhibitor of the H3K27 histone demethylases JMJD3 and UTX (IC50 = 60 nM for human JMJD3 in vitro).

GSK-LSD1 is a potent and selective inhibitor of lysine specific demethylase 1 (LSD1).

GSM-1 (GSM1) is a γ-secretase modulator that directly targets the transmembrane domain (TMD) 1 of presenilin 1, shows potent Aβ42-lowering effect (IC50=0.348 uM) in a cell-based assay.

GSM-2 is a second-generation γ-secretase modulator (GSM) that only decreases Aβ42 (IC50=65.2 nM), while inversely increasing Aβ38 and having no effect on β-CTF and Aβ40 levels.

GSTO1 inhibitor C1-27 is a potent, selective, covalent glutathione S-transferase omega 1 (GSTO1) inhibitor with IC50 of 31 nM.

GT 949 is a selective excitatory amino acid transporter-2 (EAAT2) positive allosteric modulator with an EC50 of 0.26 nM.

GTC-365 (NSC 177365) is a small drug-like pharmacological chaperone that induces cancer cell death by restoring tertiary DNA structures in mutant human telomerase reverse transcriptase (hTERT) promoters.

GTC-365 (NSC 177365) is a small drug-like pharmacological chaperone that induces cancer cell death by restoring tertiary DNA structures in mutant human telomerase reverse transcriptase (hTERT) promoters.

GTS 21 dihydrochloride is a partial agonist of α7 nicotinic acetylcholine receptors (nAChRs); also a weak α4β2 and 5-HT3 antagonist at micromolar concentrations.

Guaifenesin(Guaiphenesin)

Guanabenz (WY 8678) is an α2 adrenergic receptor agonist that is used as an antihypertensive agent, also has been proposed to exert protective effects against misfolding by interfering with eIF2α-P dephosphorylation through selective disruption of a PP1-P

Guanfacine Hydrochloride is a selective α2A-adrenoceptor agonist with anti-hypertensive effect.

Guanidinosuccinic acid is a nitrogenous metabolite isolated in excess from serum and urine.

Guanoclor is a sympatholytic drug. It is known to bind to non-adrenergic sites in pig kidney membranes.

GUT-70 is a tricyclic coumarin derived from Calophyllum brasiliense, markedly reduces cell proliferation, viability through G1 cell cycle arrest and increases apoptosis.

GV-58 is a potent, selective N-Type and P/Q-type Ca2+ Channel agonist with EC50 of 7.2 and 8.8 uM, shows no acitivity for L-type calcium channels (EC50>100 uM).

GW 1100 is a selective antagonist of GPR40-mediated Ca2+ elevations in HEK293 cells stimulated by GW 9508 (an agonist of both GPR40 and GPR120, another GPCR activated by long chain fatty acids) or linoleic acid with a pIC50 value equal to 5.99.

GW 275175X is a derivative of BDCRB that displays anti-HCMV activity by inhibition of viral DNA maturation.

GW 4064 is a selective, non-steroidal farnesoid X receptor (FXR) agonist (EC50 = 15 nM).

GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM; little activity to c-Raf1 and CDK2.

GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

GW 627368X is a selective prostanoid EP4 receptor competitive antagonist with additional affinity at TP receptors (pKi values are 7.0 and 6.8 in competition radioligand bioassays).

GW 7647 is a potent PPARα agonist with 200-fold selectivity over PPARγ and PPARδ.

GW 841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomain that displays activity in vivo against NUT-midline carcinoma, multiple myeloma, mixed-lineage leukemia, and acute myeloid leukemia..

GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

GW1929 is a synthetic peroxisome proliferator-activated receptor-γ (PPARγ) agonist with IC50 of 6.2 nM and 13 nM for human and mouse, respectively.

GW2580 is a selective inhibitor of human c-FMS with IC50 of 30 nM.

GW274150 is a novel arginine-competitive, NADPH-dependent iNOS inhibitor that has been identified from a series of acetamide amino acids that have a high selectivity for iNOS vs both eNOS (> 260-fold) and nNOS (> 219-fold) and high bioavailability (> 90%) after oral administration.Target: iNOSin vivo: GW274150 demonstrates a narrow neuroprotective therapeutic window against the toxic actions of 6-OHDA. GW274150 administration leads to a dose-dependent decrease in the number of iNOS-positive cells in the SNc of the 6-OHDA-lesioned animals. The iNOS inhibitor GW274150 fails to produce long-term neuroprotection after its withdrawal in the 6-OHDA-lesioned rat. [1]

GW311616A is a potent, intracellular human neutrophil elastase (HNE, α-1-proteinase) inhibitor.

GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively.

GW406108X (GW-406108X, GW108X) is specific inhibitor of Kif15 (Kinesin-12) with IC50 of 0.82 uM in ATPase assays.

GW4869 is a cell permeable, selective inhibitor of N-SMase (neutral sphingomyelinase).

GW501516 is the most selective and potent PPARβ (EC50=1.1nM) agonist that has been demonstrated to be 1,000-fold more selective in comparison to existing subtypes.

GW6604 is a potent and selective ALK-5 inhibitor with potent anticancer activity.

GW-766994 (GW766994) is a potent, selective, orally available CCR3 antagonist with pKi of 7.86 for inhibiting eotaxin-induced eosinophil chemotaxis in vitro assays.

GW-766994 (GW766994) is a potent, selective, orally available CCR3 antagonist with pKi of 7.86 for inhibiting eotaxin-induced eosinophil chemotaxis in vitro assays.

GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, also inhibits TGF-β type II receptor and activin type II receptor activities, but does not inhibit BMP type II receptor.

GW806742X is a novel VEGFR inhibitor.

GW843682X is a cell-permeable thiophene-benzimidazole compound and reversible PLK inhibitor

GW-8510 (GW8510) is a potent, selective inhibitor of CDK2 with IC50 of 10 nM.

GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32.

GW9662 is a selective PPAR antagonist, inhibiting PPARγ, PPARα and PPARδ with IC50 of 3.3 nM, 32 nM and 2 μM, respectively.

GWJ-A-23 (GWJ-23, GWJ23) is a potent, selective autotaxin inhibitor with Ki of 18 nM, an analog of the known ATX inhibitor S32826 and has improved aqueous solubility compared with the parent compound.

GX-674 is a potent, selective Nav1.7 inhibitor with IC50 of 0.1 nM.

GX-936 (PF 05196233) is a potent Nav1.7 inhibitor that binds to the activated state of voltage-sensor domain IV (VSD4), exhibits robust inhibition of the 1KαPMTX-evoked N1742K response with IC50 of 40 nM.

GYKI 52466 dihydrochloride is a selective non-competitive AMPA receptor antagonist (IC50 values are 10-20, ~ 450 and >> 50 μM for AMPA- , kainate- and NMDA-induced responses respectively). Skeletal muscle relaxant and orally-active anticonvulsant.

GYY 4137 is a Water-soluble, slow-releasing hydrogen sulfide donor.

GZ389988 (GZ-389988) is a novel potent, selective, locally delivered TrkA inhibitor for the treatment osteoarthritis.

GZD824 is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

GZD856 is a novel and orally bioavailable PDGFRα/β inhibitor with IC50s of 68.6 and 136.6 nM, respectively. Anti-lung cancer activities. Also a Bcr-AblT315I inhibitor with IC50s of 19.9 and 15.4 nM for Bcr-Abl and T315I mutant.

H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM, 10-fold selective for PKA than PKG, greater than 500-fold selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II.

H-151(H151) is a novel STING (stimulator of interferon genes) antagonist.

H3B-5942 is an orally available, selective estrogen receptor covalent antagonist (SERCA), demonstrates potent ERαantagonist activity in vitro and in vivo.

H3B-6527 is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity.

H3B8800 is an orally available splicing modulator that targets spliceosome SF3b complex containing either WT or mutant SF3B1 (binding IC50 of 0.3-2 nM),demonstrates dose-dependent inhibition of both canonical splicing and aberrant splicing induced by mutant SF3B1 in in vitro assays of biochemical splicing, induces lethality in spliceosome-mutant cancer cells.. H3B-8800 potently and preferentially kills spliceosome-mutant epithelial and hematologic tumor cells.

H4 Receptor antagonist 1 is a potent and selective histamine H4 receptor inverse agonist, with an IC50 of 19 nM.

H4R antagonist 1

HA130 is a selective ATX (autotaxin) inhibitor with IC50 of 28 nM.

HA14-1 is a nonpeptidic ligand of a Bcl-2 surface pocket with IC50 of~9 μM.

HA15 displayed anti-cancerous activity on all melanoma cells tested, including cells isolated from patients and cells that developed resistance to BRAF inhibitors.

Halcinonide is a high potency corticosteroid used topically in the treatment of certain skin conditions.

Halofuginone is the competitively inhibitor of prolyl-tRNA synthetase with Ki of 18.3 nM.It could also down-regulate Smad3 and blocked TGF-β signaling at 10 ng/ml in mammal.

Haloperidol (Haldol)

HAMI3379 (HAMI-3379) is a potent and selective antagonist of cysteinyl leukotriene 2 (CysLT(2)) receptor, inhibits LTD4- and LTC4-induced intracellular calcium mobilization withIC50 of 3.8 nM and 4.4 nM respectively.

HAMNO is a novel protein interaction inhibitor of replication protein A (RPA).

HAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM..

HAR-171 is a small molecule gp120-CD40 blocker that acts as a highly potent HIV entry inhibitor with IC50 of 0.43 uM against YTA48P virus with no significant cytotoxicity (CC50>120 uM)..

H-Arg-4MβNA is a substrate for cathepsin H, used for the detection of enzyme activity in gel electrophoresis.

HBT1 is a novel potent AMPA receptor potentiator with lower agonistic effect compared with LY451395 and OXP1..

HBV Capsid inhibitor 3711 (Compound 3711) is a nonnucleosidic HBV inhibitor, inhibits hepatitis B virus replication by inducing genome-free capsid formation.

HBX 19818 is a selective USP7 inhibitor with IC50 of 28.1 uM .

HBX 28258 is a potent, selective USP7 inhibitor with IC50 of 22.6 uM, exhibits high selectivity over other USP members, such as USP8, USP5, USP2, and USP20 (IC50 >200 uM), and no activity against UCH-L1, UCH-L3 and SENP1.

HBX 41108 is an inhibitor of ubiquitin-specific protease (USP) 7 activity (IC50 = 424 nM).

HC-030031 is a selective TRPA1 channel blocker that antagonizes AITC- and formalin-evoked calcium influx with IC50 of 6.2 μM and 5.3 μM respectively.

HC-056456 is an effective but not perfectly-selective blocker of CatSper channels. The [Na+]i rise is slowed by HC-056456 (IC50~3 µM).

HC-067047 is a potent and selective TRPV4 antagonist with IC50 values of 48 ± 6 nM, 133 ± 25 nM, and 17 ± 3 nM, respectively in human, rat, and mouse. Also inhibits the endogenous TRPV4-mediated response to 4α-PDH (IC50 = 22 nM).

HC-070 is a potent, selective, orally active inhibitor of TRPC4 and TRPC5 channel with IC50 of 9.3 and 46 nM (calcium influx inhibition), respectively.

hClpP activator D9 is a potent and species-selective activator of human ClpP (hClpP, human Caseinolytic protease P) by mimicking the natural chaperone ClpX..

HDAC inhibitor IV is a cell-permeable pimeloylanilide compound that acts as a FXN- (frataxin gene) specific HDAC (histone deacetylase) inhibitor.

HDAC6 degrader 9c (dHDAC6 9c) is a bifunctional molecule (dHDAC6) that could selectively degrade HDAC6, by conjugating non-selective HDAC inhibitor to a thalidomide-type E3 ligase ligand.

HDAC6-AR-IN-10 is a potent dual HDAC6/AR inhibitor with IC50 of 35.6 nM/<30 nM, shows weak inhibition on HDAC1/2/3 (IC50>1 uM).

HDAC8-IN-20a is a potent, selective HDAC8 inhibitor with IC50 of 27 nM.

HDBA, a derivative of a Streptomyces griseolavendus butyl acetate extract, is a potent inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase with an IC50 value of 0.012 µM.

HDM201 is an orally bioavailable human double minute 2 homolog (HDM2) inhibitor with potential antineoplastic activity.

HEC72702 is a novel potent, orally active inhibitor of HBV capsid assembly, inhibits HBV-DNA levels in HepG.2.2.15 cells with IC50 of 39 nM.

HEC-73543 is a novel potent, selective, orally bioavailable FLT3 inhibitor for the treatment of refractory acute myeloid leukemia (AML).

Hederacoside C is a principal bioactive pharmaceutical ingredient of Hedera helix leaf that can treat respiratory disorders, because of its expectorant, bronchodilator, antibacterial, and bronchospasmolytic effects.

Hederagenin a triterpenoid saponin, is used to study the properties of triterpenoid saponins as biopesticides that prevent fungal growth, bacterial growth, and viral plant diseases.

Hedgehog-IN-7d is a potent, cell-permeable Hedgehog (Hh) pathway inhibitor that inhibits Gli transcription activity with an IC50 value of 70 nM..

Helenalin (NSC 85236) is a sesquiterpene lactone that covalently targets Cys38 on p65 transcription factor in the canonical NF-κB signaling pathway.

Hemicholinium-3 (HC-3) is a competitive, small molecule inhibitor of choline kinase (ChoK) with ex vivo IC50 of 500 uM, also bolcks the sodium and chloride-dependent transport system and affects choline acetyltransferase.

Hemin, a physiological erythroid maturation stimulator, is able to induce the expression of critical autophagic genes (Map1a1b (LC3), Beclin-1 gen, Atg5) in an erythroleukemia cell type.

Hemoglobin modulator TD-1 (TD-1) is a novel allosteric effector of hemoglobin that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling.

Heparin Lithium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII).

Heptamethine cyanine dye-1 is a near-infrared cyanine dye for fluorescence imaging in biological systems.

HER2-IN-2 is a potent, selective HER2 inhibitor, only shows potent inhibition for EGFR and Abl in a panel of kinases.

HER2-IN-3 is a type I HER2 inhibitor that has a similar profile to HER2-IN-2.

Herboxidiene (GEX1A, TAN-1609) is a polyketide molecule first isolated from the fermentation broth of Streptomyces chromofuscus, shows in vitro antitumor activity by targeting the SF3B protein in the splicesosome.

Hesperadin inhibits Aurora B and T. brucei Aurora kinase-1 (TbAUK1) with IC50 of 250 nM and 40 nM, respectively.

Hesperidin

HET0016 (HET-0016) is a potent, selective inhibitor of CYP4A, potently inhibits the formation of 20-HETE with IC50 of 8.9 nM in human renal microsomes.

Hetrombopag is a potent, selective, orally-active Thrombopoietin (TPO) receptor agonist.

Hexacosanoic acid is a long-chain fatty acid related to various diseases such as adrenoleukodystrophy (ALD), adrenomyeloneuropathy (AMN) and atherosclerosis.

Hexadimethrine bromide is a cationic polymer discovered to enhance retroviral transduction.

Hexamethylquercetagetin is a polymethoxylated flavone in peels of citrus cultivars.

Hexaminolevulinate hydrochloride is a fluorescent agent, has approved for cystoscopic detection of papillary bladder cancer.

Hexokinase 2 modulator Comp-1 is a potent, selective small molecule modulator of Hexokinase 2 (HK2) interaction with the mitochondria, selectively dissociates HK2 from VDAC1 in vitro with IC50 of 92 nM.

HG-12-6 is a small-molecule inhibitor that bind preferentially to unphosphorylated IRAK4 with IC50 of 165.1 nM, displays 15-fold selectivity over phosphorylated IRAK4 (IC50=2876 nM).

HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.

HG6-64-1 is a potent dual TAK1 and MAP4K2 ((germinal center kinase, GCK)) inhibitor with IC50 of 41 nM and 98 nM, respectively.

HG-7-27-01 is a potent, selective c-Fes protein-tyrosine kinase inhibitor with IC50 of 224 nM, displays intermediate selectivity profiles (selectivity score=0.16) against 442 kinases..

HG-7-92-01 is a potent, selective c-Fes protein-tyrosine kinase inhibitor with IC50 of 292 nM, displays intermediate selectivity profiles (selectivity score=0.18) against 353 kinases..

HG-9-91-01 is a potent and highly selective salt-inducible kinase (SIKs) inhibitor with IC50s of 0.92 nM, 6.6 nM and 9.6 nM for SIK1, SIK2 and SIK3 respectively.

H-Gly-Arg-pNA is a colorimetric substrate for thrombin.

HhAntag is a GLI1-Mediated transcription inhibitor.

HIF2α-IN-2 is a potent, selective, allosteric inhibitor of HIF-2α PAS-B domain with Kd of 81 nM, shows high selectivity and does not affect HIF-1 function.

Highly selective group II mGlu receptor agonist (EC50 values are 2.69 and 4.48 nM for hmGlu2 and hmGlu3 respectively) that displays > 80-fold selectivity over group I and group III receptors.

H-Ile-Pro-Pro-OH, a milk-derived peptide, inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 μM. Antihypertensive tripeptides.

Hinokitiol (4-Isopropyltropolone.

Hippuristanol is a potent, steroid inhibitor of eukaryotic initiation factor 4A (eIF4A), results in cell cycle arrest at G1 phase, and induces caspases activation and apoptosis.

Hispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits TNF-α induced adhesion of monocytes to colon epithelial cells with an IC50 of 0.50 µM.

Hispidulin is a natural flavone with a broad spectrum of biological activities. Hispidulin is a Pim-1 inhibitor with an IC50 of 2.71 μM.

Darunavir(TMC114) is an HIV protease inhibitor,showed potent activity against COVID-19(SARS-COV-2) .

HIV-1 attachment inhibitor,a prodrug of the small-molecule inhibitor BMS-626529

HIV-1 inhibitor 18A is a novel broad HIV-1 inhibitor that blocks envelope glycoprotein transitions critical for entry, specifically inhibits the entry of a wide range of HIV-1 isolates with mean IC50 of 6.4 uM.

HIV-1 integrase inhibitor ((Z)-4-(3-(azidomethyl)phenyl)-2-hydroxy-4-oxobut-2-enoic acid) is uesful for anti-HIV.

HIV-1 Integrase Inhibitor 7 is an allosteric HIV-1 integrase inhibitor that inhibits the LEDGF/p75-integrase interaction with IC50 of 0.58 uM, antiviral activity EC50 of 0.76 uM..

HIV-1 integrase inhibitor, in the treatment of human immunodeficiency virus (HIV) infection.

HJC0197 is a potent Epac1 (exchange protein directly activated by cAMP 1) and Epac2 (IC50=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation. HJC0197 inhibits Epac1-mediated Rap1-GDP exchange activity at 25 μM in the presence of equal concentration of cAMP.

HJC 0726 is a potent Exchange proteins directly activated by cAMP (EPAC) inhibitor, inhibits cAMP-mediated EPAC2 GEF activity with IC50 of 1.0 uM.

HJC0152 is a signal transducer and activator of transcription 3 (STAT3) inhibitor with remarkably improved aqueous solubility.

HJC-0338 is a potent and specific EPAC2 antagonist with IC50 of 0.4 uM for competing with 8-NBD-cAMP in binding EPAC2.

HJC-0350 is a selective Epac2 inhibitor (IC50 = 0.3 μM). Displays no effect on Epac1. Blocks stimulation of the Epac2-FL FRET sensor in HEK293 cells.

HKI 357 is an irreversible dual inhibitor of the EGF receptor tyrosine kinases EGFR and HER2 (IC50s = 34 and 33 nM, respectively).

HL001 (HL 001) is a potent cyclophilin A (CypA) inhibitor with IC50 of 31.6 nM, induces NSCLC cell cycle arrest and apoptosis via restoring p53 expression.

HLCL-61 is a first-in-class small-molecule inhibitor of PRMT5 for treatment of acute myeloid leukemia.

HlyU inhibitor CM14 (1025E12) is a specifc, small-molecule inhibitor of transcriptional regulator HlyU activity with EC50 of 30.97 uM, inhibits HlyU from binding to target DNA by covalently modifying Cys30.

HM30181 is a potent and selective inhibitor of P-glycoprotein.

HM30181 mesylate is a competitive and potent P-glycoprotein inhibitor.

HM-61713 (BI-1482694) is an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.

HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.

HMN-176 is a stilbene derivative which inhibits mitosis without significant effect on tubulin polymerization.

HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM.

HMPC is a novel bacteriostatic agent that shows bacteriostatic activity against S. aureus (MIC=4 μg/ml) and rescues Caenorhabditis elegans from S. aureus infection.

HMS-101 (HMS101) is a potent, selective mutant IDH1 inhibitor, the IC50 is significantly lower in mouse bone marrow cells transduced with IDH1mut compared with IDH1wt (1 uM vs 12 uM, respectively).

HOE-140 (Icatibant) is a potent and selective bradykinin B2 receptor antagonist (pA2 = 9.04). Also inhibits aminopeptidase N (Ki = 9.1 μM).

Hoechst 33342 3Hcl(HOE 33342 3Hcl) is an AT-specific DNA minor groove ligand used fluorochrome for visualizing cellular DNA.

Hoechst stains are part of a family of blue fluorescent dyes used to stain DNA.

HOIPIN-1 (JTP-0819958, HOIP inhibitor-1) is a chemical inhibitor of linear ubiquitin chain assembly complex (LUBAC, IC50=2.8 uM), specifically generates Met1-linked linear ubiquitin chains through the ubiquitin ligase activity in HOIP, and activates the N

HOIPIN-8 (HOIP inhibitor-8) is a potent chemical inhibitor of linear ubiquitin chain assembly complex (LUBAC, IC50=11 nM), specifically generates Met1-linked linear ubiquitin chains through the ubiquitin ligase activity in HOIP, and activates the NF-kB pa

Homoharringtonine(HHT) is a cytotoxic alkaloid from the evergreen tree.

Homoplantaginin is a flavonoid from a traditional Chinese medicine Salvia plebeia with antiinfammatory and antioxidant properties.

Honokiol(NSC-293100), a hydroxylated biphenyl compound isolated from the Chinese herb Magnolia officinalis, has been reported to have anticancer activities in a variety of cancer cell lines.

Hosenkoside A is a baccharane glycoside isolated from the seeds of impatiens balsamina.

Hosenkoside B is a baccharane glycoside isolated from the seeds of impatiens balsamina.

Hosenkoside F is a baccharane glycoside isolated from the seeds of impatiens balsamina.

Hosenkoside K is a baccharane glycoside isolated from the seeds of impatiens balsamina.

Hosenkoside M is a baccharane glycoside isolated from the seeds of impatiens balsamina.

HPGDS inhibitor 1 is a novel and selective Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50 Value of 0.7 nM.

hPGDS-IN-1 is a potent, selective hPGDS inhibitor with IC50 of 12 nM in FP or EIA assays..

HPI-1 is a Hedgehog (Hh) pathway inhibitor that suppresses signaling through Shh (IC50=1.5 uM) without significantly affecting Wnt signaling (IC50>30 uM).

HPOB is a novel selective inhibitor of HDAC6 catalytic activity in vivo and in vitro.

HS-10 is a novel Hsp90 inhibitor increases the Tm of Hsp90 by 10.5°C.

HS-10296 hydrochloride is an orally available and third-Generation inhibitor of epidermal growth factor receptor (EGFR)-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.

HS-10296 is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity.

HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis.

HS148 (DAPK3 inhibitor HS148) is a selective DAPK3 inhibitor with Ki of 119 nM, >10-fold selectivity over Pim kinases..

HS-152 (HS152) is a specific small-molecule inhibitor of SMAD ubiquitin regulatory factor 1 (SMURF1), not only potently inhibits SMURF1-mediated RHOB degradation with IC50 of 3.2 uM, but also strongly blocks SMURF1-mediated RHOA and SMAD1 degradation (IC5

HS-173 is a potent PI3Kα inhibitor with IC50 of 0.8 nM.

HS220 (HS-220) is a Plasmodium-selective takinib analog that targets atypical P. falciparum protein kinase 9 (PfPK9, Kd=4.1 uM) but does not inhibit HsTAK1, decreases K63-linked ubiquitination in P. falciparum; inhibits P. berghei parasite load in HuH7 ce

Hs-27 is a Novel Hsp90 Inhibitor, Exhibits Diagnostic and Therapeutic Potential in Triple Negative Breast Cancer.

HS-38 is a potent and selective DAPK1 and DAPK3 (ZIPK) inhibitor with IC50 of 200 nM for DAPK1 and Kd of 280 nM for ZIPK, also inhibits Pim3 (IC50=200 nM), and displays no activity against Src or Abl, little activity against EGFR;

HS56 (Pim-DAPK3 inhibitor HS56) is a potent, dual Pim/DAPK3 inhibitor with Ki of 72 nM (Pim-3) and 315 nM (DAPK3), shows micromolar potency toward Pim-1 and Pim-2 (Ki=1.5 and 17 uM).

HS-72 is an allosteric, selective, cell-permeable inhibitor of inducible Hsp70 (Hsp70i or Hsp72), shows selectivity for Hsp70i over the closely related Hsc70 as well as the broader purinome.

HS94 (DAPK3 inhibitor HS94) is a selective DAPK3 inhibitor with Ki of 126 nM, >20-fold selectivity over Pim kinases..

HSD1169 is a potent, dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations (D835 or F691, Kd=1-5 nM), potently inhibits acute myeloid leukemia cell lines (IC50=5 nM).

HSD992 is a potent, selective CDK2/3 inhibitor with moderate CDK9 inhibition with IC50 of 18 nM, 57 nM and 49 nM for CDK3/cyclin E, CDK2/cyclin A1 and CDK2/cyclin E, respecively.

HSF1A is a cell-permeable activator of heat shock transcription factor 1 (HSF1).

HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities.

hSMG-1 inhibitor 11e is a potent, selective hSMG-1 kinase inhibitor with IC50 of <0.05 nM, >900-fold selectivity over mTOR, and no significant activity against CDK1/2..

hSMG-1 inhibitor 11j is a potent, selective hSMG-1 kinase inhibitor with IC5 0of 0.11 nM, 455-fold selectivity over mTOR and no activity against CDK1/2.

HSP27 inhibitor J2 is a small molecule functional inhibitor of Hsp27, induces significant abnormal HSP27 dimer formation in cancer cells.

HSP70 modulator 115-7c is an artificial co-chaperone, enhancer of Hsp70, stimulats the ATPase and protein-folding activities of a prokaryotic Hsp70 (DnaK) and partially compensated for a Hsp40 loss-of-function mutation in yeast.

HSP70-IN-1 is a heat shock protein (HSP) inhibitor; inhibits the growth of Kasumi-1 cells with an IC50 of 2.3 μM.

HSP990 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity.

HT-0712 (IPL-455903) is a novel potent, selective PDE4 inhibitor with IC50 of 0.15 uM for PDE4D3, without effect on PDE1B, PDE3A, and PDE10A.

HT-2157 (SNAP 37889) is a selective, high-affinity, competitive antagonists of galanin-3 receptor (Gal3).

hTG2 inhibitor VA4(VA4) is a novel potent, irreversible inhibitor of human tissue transglutaminase (hTG2) with Ki of 12.9 uM, allosterically abolishs its GTP binding ability with a high degree of selectivity and efficiency.

HTH-01-015 is a selective inhibitor of NUAK1 kinase with an IC50 value of 100 nM.

HTH-01-091 is a potent and selective, cell-permeable, ATP-competitive MELK inhibitor with biochemical IC50 of 10.5 nM.

HTHQ, which is a hydroquinone monoalkyl ether, is a potent anti-oxidative agent, even at low dose levels.

HTS01037 is a highly potent ligand of adipocyte fatty acid binding protein (A-FABP/aP2) with Ki of 0.67 uM.

HUHS015 is a prostate cancer antigen (PCA)-1/AlkB homologue 3 (ALKBH3) inhibitor.

Huperzine A, an active Lycopodium alkaloid extracted from traditional Chinese herb, is a potent, selective and reversible acetylcholinesterase (AChE) inhibitor and has been widely used in China for the treatment of Alzheimer's disease (AD).